Archives
Phenothiazines Boost Macrophage Antibacterial Action via ROS
2026-04-12
Phenothiazines Boost Macrophage Antibacterial Action via ROS and Autophagy
Study Background and Research Question
Bacterial infections remain a leading cause of global morbidity and mortality, exacerbated by the accelerating crisis of antibiotic resistance. Intracellular pathogens, such as Salmonella enterica serovar Typhimurium and Shigella flexneri, evade conventional antibiotics by residing within host cells, particularly macrophages. As antibiotics alone increasingly fail to control these pathogens, attention has shifted toward host-directed therapies (HDTs) that activate innate immune responses and circumvent resistance mechanisms. Phenothiazines, a class of compounds known primarily as antipsychotic agents and dopamine receptor antagonists, have been previously observed to restrict intracellular bacterial replication, but the underlying cellular mechanisms remained unclear [source_type: paper | source_link: https://doi.org/10.3389/fimmu.2025.1712724].Key Innovation from the Reference Study
The reference study by Qiu et al. (2025) delivers a significant advance by elucidating how phenothiazines, beyond their well-characterized neuropharmacological actions, directly enhance macrophage-mediated antibacterial activity. The authors demonstrate that phenothiazines potentiate the innate immune function of macrophages through the coordinated induction of reactive oxygen species (ROS) and autophagy, two critical cellular defense processes against intracellular pathogens [source_type: paper | source_link: https://doi.org/10.3389/fimmu.2025.1712724]. This represents a paradigm shift, positioning phenothiazines not only as neuroactive modulators but also as prototypes for host-targeted anti-infective agents.Methods and Experimental Design Insights
The study leveraged both in vitro and in vivo approaches to dissect the impact of phenothiazines on macrophage function:- Murine bone marrow-derived macrophages (BMDMs) were treated with various phenothiazines and subsequently infected with intracellular bacteria, including S. Typhimurium and S. flexneri.
- Lysosomal activity assays and autophagic flux measurements (e.g., LC3-II accumulation) quantified changes in degradative capacity and autophagy induction.
- ROS generation was detected using established fluorescent probes.
- Pharmacological inhibitors—autophagy blockers and ROS scavengers—were applied to mechanistically dissect the dependency of observed antibacterial effects on these pathways.
- In vivo efficacy was assessed by administrating perphenazine in mouse models of S. Typhimurium infection to monitor organ pathology and inflammatory markers.
Core Findings and Why They Matter
The authors report several converging lines of evidence:- Enhanced Macrophage Antibacterial Activity: Phenothiazine-treated macrophages exhibited a striking increase in their ability to suppress intracellular bacterial replication. This effect was not due to direct bactericidal action but was mediated by host cell processes [source_type: paper | source_link: https://doi.org/10.3389/fimmu.2025.1712724].
- Autophagy Induction: Phenothiazines triggered robust autophagic responses in macrophages, as shown by increased LC3-II and lysosomal activity. Inhibition of autophagy largely abrogated the antibacterial effect, underscoring its necessity in the observed phenotype.
- ROS Generation: Treatment also led to elevated ROS levels, essential for intracellular pathogen clearance. The application of ROS scavengers diminished the antibacterial activity, confirming the mechanistic requirement for oxidative stress.
- Synergistic Interaction: The antibacterial effect was maximized when both autophagy and ROS pathways were intact, highlighting a coordinated host defense mechanism potentiated by phenothiazines.
- In Vivo Validation: Perphenazine treatment in infected mice reduced organ lesions and inflammation, further supporting translational potential.
Comparison with Existing Internal Articles
Internal literature from APExBIO and collaborators has long recognized the multipurpose value of Chlorpromazine HCl—a prototypical phenothiazine—across neuropharmacology and infection biology. For example, “Chlorpromazine HCl: Bridging Dopamine Receptor Antagonism...” [source_type: internal_article | source_link: https://etripamilcompounds.com/index.php?g=Wap&m=Article&a=detail&id=88] highlights the compound’s dual role as a dopamine receptor antagonist and a tool for dissecting endocytic and immune pathways. Similarly, “Chlorpromazine HCl: From Dopamine Antagonism to Cell Biol...” [source_type: internal_article | source_link: https://bkm120.net/index.php?g=Wap&m=Article&a=detail&id=15447] discusses its applications in both psychotic disorder research and infection models, anticipating the current reference study’s demonstration of phenothiazines’ immunomodulatory potential. These articles collectively support the notion that dopamine receptor inhibition and GABAA receptor modulation, hallmarks of neuropharmacology studies, can intersect with cell-autonomous immunity and host-pathogen research.Protocol Parameters
- cell-based infection assay | 10–100 μM Chlorpromazine HCl | macrophage antibacterial studies | Range validated for autophagy and ROS induction without overt cytotoxicity [source_type: product_spec | source_link: https://www.apexbt.com/chlorpromazine-hcl.html]
- cell-based infection assay | 20–50 μM Chlorpromazine HCl | intracellular bacterial killing | Supported by phenothiazine screening in macrophage infection models [source_type: workflow_recommendation | source_link: https://doi.org/10.3389/fimmu.2025.1712724]
- autophagy detection | LC3-II immunoblot | autophagic flux quantification | Standard marker for autophagy in phenothiazine-treated cells [source_type: paper | source_link: https://doi.org/10.3389/fimmu.2025.1712724]
- ROS measurement | fluorescent probe (e.g., DCFDA) | oxidative burst analysis | Validated for macrophages following phenothiazine exposure [source_type: paper | source_link: https://doi.org/10.3389/fimmu.2025.1712724]
Limitations and Transferability
Despite demonstrating robust enhancement of macrophage antibacterial function, the study’s scope is subject to several limitations:- Compound Specificity: While broad phenothiazine activity was observed, the molecular specificity of each compound for distinct host targets (e.g., dopamine receptor antagonism versus unrelated targets) remains to be fully clarified [source_type: paper | source_link: https://doi.org/10.3389/fimmu.2025.1712724].
- In Vivo Safety: The translational potential of repurposing antipsychotics for infectious disease will require careful titration to avoid adverse neurological or off-target effects.
- Pathogen Scope: The primary focus was on a subset of intracellular bacteria; generalizability to other pathogens is promising but not yet confirmed.
- Mechanistic Resolution: While autophagy and ROS were established as necessary, the upstream signaling events linking phenothiazine exposure to these pathways require further study.